-
-
-
-
-
-
-
Avalo Therapeutics names Kevin Lind to board of directors
-
-
-
-
-
-
-
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Avalo Reports 2023 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
-
-
-
-
-
-
1,161,998 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

